Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH)

Disease Sites:

Adrenocortical, Bladder, Breast, Cervical, Colon, Dermatologic, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Gynecologic, Head/Neck, Kidney (Renal Cell), Liver, Lung, Melanoma, Miscellaneous, Ovarian, Pancreatic, Prostate, Rectal, Sarcoma, Thyroid, Urologic, Uterine

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Enfortumab Vedotin ejfv, Sacituzumab govitecan, Trastuzumab Deruxitecan (DS-8201a)

Principal Investigator(s):

Keedy, Vicki

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

10-21-2025

Trial Type:

Treatment

Protocol ID:

ETCMD10397

National Clinical Trial ID:

NCT06311214

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH)

Eligibility